CWBR CohBar, Inc. Stock Quote

CWBR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	2.90%	Shs Outstand	50.20M	Perf Week	-12.07%
Market Cap	98.39M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.38%	Shs Float	43.48M	Perf Month	-19.47%
Income	-15.30M	PEG	-	EPS next Q	-0.06	Inst Own	14.00%	Short Float	6.59%	Perf Quarter	21.43%
Sales	-	P/S	-	EPS this Y	20.00%	Inst Trans	12.27%	Short Ratio	4.12	Perf Half Y	57.73%
Book/sh	0.38	P/B	4.03	EPS next Y	-6.50%	ROA	-97.40%	Target Price	-	Perf Year	-8.93%
Cash/sh	0.36	P/C	4.20	EPS next 5Y	-	ROE	-150.60%	52W Range	0.85 - 4.25	Perf YTD	14.18%
Dividend	-	P/FCF	-	EPS past 5Y	-16.70%	ROI	-	52W High	-64.00%	Beta	2.73
Dividend %	-	Quick Ratio	10.30	Sales past 5Y	-	Gross Margin	-	52W Low	80.00%	ATR	0.19
Employees	12	Current Ratio	10.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	41.84	Volatility	10.69% 10.49%
Optionable	No	Debt/Eq	0.19	EPS Q/Q	17.50%	Profit Margin	-	Rel Volume	0.55	Prev Close	1.56
Shortable	Yes	LT Debt/Eq	0.16	Earnings	Nov 16 AMC	Payout	-	Avg Volume	695.92K	Price	1.53
Recom	2.00	SMA20	-13.80%	SMA50	-3.54%	SMA200	0.01%	Volume	382,454	Change	-1.92%

Feb-25-21 09:00AM	CohBar to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire -7.14%
Feb-09-21 09:00AM	CohBar to Present at the BIO CEO & Investor Digital Conference GlobeNewswire
Jan-20-21 09:00AM	CohBar to Present at the 3rd Annual Longevity Therapeutics Conference GlobeNewswire +6.38%
Jan-11-21 09:00AM	CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS GlobeNewswire
Dec-09-20 09:00AM	CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model GlobeNewswire
Nov-19-20 09:00AM	CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference GlobeNewswire
Nov-16-20 04:01PM	CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +5.50%
03:15PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
Nov-09-20 03:30PM	These 3 Penny Stocks Could Rally Over 100%, Says Roth Capital TipRanks +8.48%
Nov-02-20 09:00AM	CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020 GlobeNewswire
07:35AM	Forget Bargain Hunting: Play 5 Stocks With Rising P/E Zacks
Oct-29-20 09:00AM	CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Oct-27-20 09:00AM	CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event GlobeNewswire
Oct-26-20 09:00AM	CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model GlobeNewswire
Oct-15-20 04:05PM	CohBar to Present at the BIO-Europe Conference GlobeNewswire
Oct-08-20 09:00AM	CohBars CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference GlobeNewswire
Oct-05-20 09:00AM	CohBar to Present at the BIO Investor Forum GlobeNewswire
Sep-29-20 04:05PM	CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference GlobeNewswire
Sep-10-20 04:05PM	CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit GlobeNewswire
Sep-04-20 11:24AM	Insider Buys CohBar's Stock Benzinga +6.00%
Sep-03-20 08:45AM	CohBar to Present at the H.C. Wainwright Annual Global Investment Conference GlobeNewswire -10.71%
Aug-28-20 04:05PM	CohBar Announces Closing of Public Offering of Common Stock and Warrants GlobeNewswire +8.00%
Aug-26-20 08:30AM	CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants GlobeNewswire -32.64%
Aug-25-20 04:55PM	CohBar Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
Aug-24-20 09:00AM	CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity GlobeNewswire
Aug-13-20 04:03PM	CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-05-20 09:00AM	CohBar Presents New Antifibrotic Data at the American Thoracic Societys Virtual 2020 Conference GlobeNewswire +8.39%
Jul-30-20 09:00AM	CohBar to Announce 2020 Second Quarter Financial Results and Provide Business Update on August 13, 2020 GlobeNewswire
Jul-07-20 09:00AM	CohBar Resumes CB4211 Phase 1b Clinical Trial GlobeNewswire
Jul-06-20 09:00AM	CohBar to Present at Sachs Novel Coronavirus Investment Forum GlobeNewswire +6.00%
Jun-30-20 09:00AM	CohBar Added to Russell 2000® Index and Raises $4.4M in ATM Offering GlobeNewswire
Jun-17-20 09:00AM	CohBar Founder Dr. Nir Barzilais New Book AGE LATER Reveals that Aging Can Be Seen as a Preventable Disease GlobeNewswire
Jun-02-20 09:00AM	CohBar to Hold 2020 Annual Shareholder Meeting and Investor Update June 16, 2020 GlobeNewswire +6.43%
May-27-20 09:00AM	CohBars CEO to Participate on the New Breakthroughs in Aging Biology Panel at the BIO 2020 Digital Conference GlobeNewswire
May-14-20 04:02PM	CohBar Reports First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire -12.50%
May-13-20 09:00AM	CohBars Chief Operating Officer Jon Stern Plans to Step Down from Management Role GlobeNewswire -8.72%
May-05-20 09:00AM	CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides GlobeNewswire +19.40%
May-01-20 11:00AM	CohBars Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine GlobeNewswire +10.98%
Apr-30-20 09:00AM	CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020 GlobeNewswire -6.25%
Apr-19-20 09:21AM	Is CohBar, Inc. (NASDAQ:CWBR) A Volatile Stock? Simply Wall St.
Apr-14-20 08:30AM	CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference GlobeNewswire +5.79%
Mar-30-20 08:45AM	CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity GlobeNewswire -18.37%
Mar-12-20 04:02PM	CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update GlobeNewswire -17.05%
03:00PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
08:30AM	CohBar to Hold Investor Meetings at the ROTH Virtual Conference GlobeNewswire
Mar-02-20 04:30PM	CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020 GlobeNewswire
Jan-28-20 09:00AM	CohBar to Present at the 2020 BIO CEO & Investor Conference GlobeNewswire
Jan-22-20 09:00AM	CohBar Appoints Jordyn Tarazi as Director of Investor Relations GlobeNewswire +9.66%
Jan-08-20 09:00AM	CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis GlobeNewswire
Dec-23-19 08:04PM	Hedge Funds Have Never Been This Bullish On CohBar, Inc. (CWBR) Insider Monkey
Dec-16-19 09:00AM	CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis GlobeNewswire +9.25%
Nov-06-19 04:04PM	CohBar Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire -7.77%
Nov-05-19 09:00AM	CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity GlobeNewswire
Oct-24-19 09:00AM	CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019 GlobeNewswire
Oct-23-19 08:45AM	CohBar Expands Board with Biotech Veteran Misha Petkevich GlobeNewswire +5.96%
Oct-15-19 09:00AM	CohBar to Present at the 2019 BIO Investor Forum GlobeNewswire
Aug-07-19 04:05PM	CohBar Reports Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Jul-31-19 04:05PM	CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019 GlobeNewswire
Jun-10-19 09:00AM	CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions GlobeNewswire +18.29%
Jun-05-19 09:00AM	CohBar to Hold 2019 Annual Shareholder Meeting and Investor Update June 18, 2019 GlobeNewswire -14.36%
May-29-19 09:00AM	CohBar to Present Data on Novel Analogs of a Mitochondrially Encoded Peptide with Beneficial Effects in an Animal Model of Type 2 Diabetes at the American Diabetes Association 79th Scientific Sessions GlobeNewswire
May-07-19 04:03PM	CohBar Reports First Quarter 2019 Financial Results and Business Update GlobeNewswire
03:00PM	CohBar, Inc. to Host Earnings Call ACCESSWIRE
09:00AM	CohBar Appoints Steven B. Engle as Chief Executive Officer GlobeNewswire
Apr-26-19 03:35PM	CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019 GlobeNewswire +5.93%
Apr-23-19 09:00AM	CohBar Announces Key Opinion Leader Conference Call and Webcast GlobeNewswire
Apr-22-19 09:00AM	CohBar Announces the Appointment of David Greenwood to its Board of Directors GlobeNewswire -7.50%
Mar-18-19 04:03PM	CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update GlobeNewswire -8.68%
Mar-04-19 09:00AM	CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019 GlobeNewswire
Feb-11-19 09:00AM	CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors GlobeNewswire
Dec-10-18 04:05PM	CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer GlobeNewswire
Nov-29-18 08:40AM	Research Report Identifies Equinix, Universal Electronics, LHC Group, Cohbar, Amgen, and Aetna with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-26-18 09:00AM	CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize GlobeNewswire
Nov-14-18 04:03PM	CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire -11.17%
Nov-08-18 09:00AM	CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazines Health Care 50 GlobeNewswire
Nov-05-18 09:00AM	CohBar Provides Update on CB4211 Clinical Trial GlobeNewswire -16.59%
Oct-31-18 09:00AM	CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018 GlobeNewswire
Oct-22-18 08:20AM	Recent Analysis Shows Renren, LiveXLive Media, Pivotal Software, Sun Life Financial, Gold Standard Ventures, and Cohbar Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-25-18 09:00AM	CohBar Engages LifeSci Advisors as Investor Relations Partner GlobeNewswire
Aug-14-18 04:03PM	CohBar Announces Second Quarter 2018 Financial Results GlobeNewswire
Aug-02-18 01:09PM	CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018 GlobeNewswire
Jul-12-18 09:00AM	CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH GlobeNewswire
Jun-27-18 04:05PM	CohBar Completes Sale of $20 Million Under Controlled Equity Offering GlobeNewswire
09:00AM	CohBar Added to Russell 2000® Index GlobeNewswire
Jun-25-18 12:08PM	CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions GlobeNewswire
Jun-07-18 08:59AM	CohBar Announces the Appointment of Dr. Philippe Calais to its Board GlobeNewswire
Jun-06-18 09:45AM	CohBar to Hold 2018 Annual Shareholder Meeting and Investor Update, June 19, 2018 GlobeNewswire +16.12%
May-29-18 09:00AM	CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions GlobeNewswire
May-15-18 04:03PM	CohBar, Inc. Announces First Quarter 2018 Financial Results GlobeNewswire
Apr-18-18 04:05PM	CohBar, Inc. Announces Voluntary Delisting from the TSX Venture Exchange GlobeNewswire
Apr-13-18 04:05PM	CohBar, Inc. Announces Closing of Private Placement for Aggregate Gross Proceeds of Approximately $3,900,000 GlobeNewswire
Apr-02-18 04:03PM	CohBar, Inc. Announces Fourth Quarter 2017 Financial Results GlobeNewswire
Mar-29-18 04:10PM	CohBar, Inc. Announces Closing of First Tranche of Private Placement GlobeNewswire
Mar-26-18 09:00AM	CohBar, Inc. Announces Financing of up to US$5,000,000 in Unsecured Promissory Notes GlobeNewswire
Mar-19-18 04:35PM	CohBar, Inc. to Announce 2017 Fourth Quarter Financial Results and Host Conference Call for Shareholders on April 2, 2018 GlobeNewswire
Jan-16-18 07:00AM	OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire

CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. The company was founded in 2007 and is headquartered in Menlo Park, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cundy Kenneth C	Chief Scientific Officer	Feb 16	Option Exercise	0.73	10,000	7,300	20,000	Feb 18 04:30 PM
Cundy Kenneth C	Chief Scientific Officer	Feb 16	Sale	1.90	10,000	19,000	10,000	Feb 18 04:30 PM
Petkevich Misha	Director	Sep 03	Buy	1.02	11,000	11,220	240,609	Sep 04 09:00 AM
Petkevich Misha	Director	Sep 02	Buy	1.00	6,000	6,000	229,609	Sep 03 09:07 AM
Cundy Kenneth C	Chief Scientific Officer	Aug 06	Option Exercise	0.73	10,000	7,300	20,000	Aug 10 04:13 PM
Cundy Kenneth C	Chief Scientific Officer	Aug 06	Sale	1.90	10,000	19,000	10,000	Aug 10 04:13 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience